成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. Metabolic Enzyme/Protease
  2. Phospholipase
  3. Tanshinone I

Tanshinone I  (Synonyms: Tanshinone A)

目錄號(hào): HY-N0134 純度: ≥98.0%
COA 產(chǎn)品使用指南 技術(shù)支持

Tanshinone I 是一種IIA型人重組 sPLA2 和兔重組 cPLA2 抑制劑,IC50 分別為 11 μM 和 82 μM。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Tanshinone I Chemical Structure

Tanshinone I Chemical Structure

CAS No. : 568-73-0

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機(jī)構(gòu)(單位)一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
5 mg ¥400
In-stock
10 mg ¥570
In-stock
25 mg ¥991
In-stock
50 mg ¥1463
In-stock
100 mg ¥2163
In-stock
500 mg ¥5325
In-stock
1 g   詢價(jià)  
5 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Tanshinone I:

查看 Phospholipase 亞型特異性產(chǎn)品:

  • 生物活性

  • 實(shí)驗(yàn)參考方法

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Tanshinone I is an inhibitor of type IIA human recombinant sPLA2 (IC50=11 μM) and rabbit recombinant cPLA2 (IC50=82 μM).

IC50 & Target

IC50: 11 μM (sPLA2), 82 μM (cPLA2)[1].

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
AGS IC50
> 50 μM
Compound: 6, tanshinone i
Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay
Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay
[PMID: 17583950]
AGS IC50
12.5 μM
Compound: 6, tanshinone i
Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay
Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay
[PMID: 17583950]
Hep 3B2 EC50
> 10 μM
Compound: 3
Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay
Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay
[PMID: 20455578]
Hep 3B2 IC50
> 50 μM
Compound: 6, tanshinone i
Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay
Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay
[PMID: 17583950]
Hep 3B2 IC50
8.51 μM
Compound: 6, tanshinone i
Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay
Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay
[PMID: 17583950]
HepG2 EC50
> 10 μM
Compound: 3
Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay
Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay
[PMID: 20455578]
HepG2 EC50
6.3 μM
Compound: 3
Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay
Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay
[PMID: 20455578]
KB IC50
5.87 μM
Compound: 1
Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay
[PMID: 29294282]
MCF7 IC50
7.927 μM
Compound: 1
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 33751939]
MDA-MB-231 IC50
7.962 μM
Compound: 1
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 33751939]
MIA PaCa-2 IC50
10.5 μM
Compound: 15
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT assay
[PMID: 21775156]
PLC-PRF-5 EC50
> 10 μM
Compound: 3
Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay
Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay
[PMID: 20455578]
Vero C1008 CC50
> 200 μM
Compound: 29
Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay
Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability treated for 24 hrs by CCK8 assay
[PMID: 35620927]
體外研究
(In Vitro)

Tanshinone I inhibits PGE2 formation from LPS-induced RAW macrophages (IC50=38 μM). When Tanshinone I is added simultaneously with LPS, this compound clearly inhibits PGE2 production (IC50=38 μM) at 10-100 μM. Tanshinone I also reduces PGE2 production (IC50=46 μM) when added after COX-2 is fully induced. The fact that Tanshinone I inhibits PGE2 production by pre-induced COX-2 strongly suggests that this compound may directly inhibit COX-2 activity and/or affect PLA2 activity. When Tanshinone I is incubated with two different forms of phospholipase A2 (PLA2), it clearly inhibits sPLA2 (IC50=11 μM) in a concentration-dependent manner. Although being less potent, Tanshinone I also inhibits cPLA2 (IC50=82 μM)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Tanshinone I shows antiinflammatory activity in rat carrageenan-induced paw oedema and adjuvant-induced arthritis. In order to establish the anti-inflammatory activity of Tanshinone I, the classical animal models of acute and chronic inflammation [rat carrageenan (CGN)-induced paw oedema and rat adjuvant-induced arthritis (AIA)] are employed. When Tanshinone I is orally administered, it shows significant anti-inflammatory activity against CGN-induced paw oedema (47% inhibition at 160 mg/kg), while the IC50 of indomethacin is 7.1 mg/kg. In AIA, Tanshinone I gives 27% inhibition of secondary inflammation at 18 day with an oral dose of 50 mg/kg/day, whereas prednisolone (5 mg/kg/day) shows potent inhibition (65%)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

276.29

Formula

C18H12O3

CAS 號(hào)
性狀

固體

顏色

Light brown to black

中文名稱

丹參酮 I

結(jié)構(gòu)分類
初始來(lái)源
運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn): 

DMSO 中的溶解度 : 2 mg/mL (7.24 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響,請(qǐng)使用新開(kāi)封的 DMSO)

配制儲(chǔ)備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 3.6194 mL 18.0969 mL 36.1939 mL
5 mM 0.7239 mL 3.6194 mL 7.2388 mL
查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用, -20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物溶解方案計(jì)算器
請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息:

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

由于實(shí)驗(yàn)過(guò)程有損耗,建議您多配一只動(dòng)物的量
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
純度 & 產(chǎn)品資料

純度: ≥98.0%

參考文獻(xiàn)
Kinase Assay
[1]

As sources of PLA2, human recombinant sPLA2 (type IIA) is purified from CHO cells transfected with the PLA2 gene and rabbit recombinant platelet cPLA2 is obtained through its expression in baculovirus. The standard reaction mixture (200 μL) contained 100 mM Tris-HCl buffer (pH 9.0) with 6 mM CaCl2 and 20 nmol 1-acyl-[1-14C]-arachidonyl-sn-glycerophosphoethanolamine (2000 cpm/nmol) in the presence or absence of Tanshinone I. The reaction is started by adding 50 ng purified sPLA2 or cPLA2. After 20 min at 37°C, the free fatty acid generated is analysed. Under these standard conditions, the reaction mixture in the absence of Tanshinone I released approximately 10% of free fatty acid from the phospholipid substrate added[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

RAW 264.7 cells are cultured with DMEM supplemented with 10% FBS and 1% antibiotics under 5% CO2 at 37°C. Briefly, cells are plated in 96-well plates (2×105 cells/well). LPS (1 ug/mL) and Tanshinone I are simultaneously added and incubated for 24 h, unless otherwise specified. The PGE2 concentration in the medium is measured using an EIA kit for PGE2. In order to determine the effects of Tanshinone I on PGE2 production after induction of COX-2, cells are incubated with LPS (1 ug/mL) for 24 h and thoroughly washed. Then, Tanshinone I is added without LPS and the cells are incubated for another 24 h. From the medium, PGE2 concentrations are measured. The cytotoxicity of Tanshinone I to RAW cells is checked using the MTT assay. Tanshinone I does not show any cytotoxicity up to 100 uM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Mice[1]
In order to evaluate the inhibitory activity of Tanshinone I against animal models of acute and chronic inflammation, rat carrageenan (CGN)-induced paw oedema and adjuvant-induced arthritis (AIA) models are employed. Briefly, 1% CGN dissolved in pyrogen-free saline (0.05 mL) is injected into right hind paw of rats for the paw oedema test. After 5 h, swelling of the treated paw is measured using a plethysmometer. Tanshinone I dissolved in 0.5% CMC is administered orally 1 h prior to CGN injection. For the AIA test, an arthritic inflammation is provoked by injection of Mycobacterium Butyricum (0.6 mL/rat) dissolved in mineral oil to the right hind paw of rats. Tanshinone I is orally administered every day. The swelling of the treated and untreated paws is measured using a plethysmometer.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻(xiàn)

完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用, -20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?年內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.6194 mL 18.0969 mL 36.1939 mL 90.4846 mL
5 mM 0.7239 mL 3.6194 mL 7.2388 mL 18.0969 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱:

 

* 需求量:

* 客戶姓名:

 

* Email:

* 電話:

 

* 公司或機(jī)構(gòu)名稱:

   留言給我們:

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱:
Tanshinone I
目錄號(hào):
HY-N0134
需求量: